BIBP 3226 inhibition of nicotinic receptor mediated chromaffin cell secretion

被引:2
|
作者
Zhang, PJ [1 ]
Zheng, JL [1 ]
Hexum, TD [1 ]
机构
[1] Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA
关键词
neuropeptide Y; BIBP; 3226; catecholamine secretion; chromaffin cell;
D O I
10.1016/S0014-2999(98)00729-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
(R)-N-2-(diphenacetyl)-N-[(4-hydroxypheny)methyl]-arginiamide (BIBP 3226) is a selective neuropeptide Y Y-1 receptor antagonist with structural similarity to the C-terminal tripeptide of neuropeptide Y. Based on this similarity we questioned whether BIBP 3226 could act as an agonist. Incubation of BIBP 3226 with bovine chromaffin cells in culture results in the inhibition of nicotinic receptor-stimulated catecholamine secretion (IC50 = 2.4 mu M). The effect of BIBP 3226 is independent of neuropeptide Y action since the presence of neuropeptide Y in the culture medium does not alter the effect of BIBP 3226. BIBP 3226 decreased the efficacy of the nicotinic receptor agonist, 1,1-dimethyl-4-phenylpiperizinium (DMPP), but did not change its potency suggesting non-competitive inhibition. BIBP 3226 has a similar effect on nicotinic receptor-stimulated Ca-45(2+) influx. BIBP 3226 does not inhibit [H-3]norepinephrine release induced by high K+ and its effect is not pertussis toxin-sensitive. We conclude that not only can BIBP 3226 act as a neuropeptide Y receptor antagonist in bovine chromaffin cells but also act as an agonist and inhibit catecholamine secretion. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:121 / 125
页数:5
相关论文
共 50 条
  • [21] PHARMACOLOGICAL CHARACTERIZATION OF THE SELECTIVE NONPEPTIDE NEUROPEPTIDE-Y Y1 RECEPTOR ANTAGONIST BIBP-3226
    DOODS, HN
    WIENEN, W
    ENTZEROTH, M
    RUDOLF, K
    EBERLEIN, W
    ENGEL, W
    WIELAND, HA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 275 (01): : 136 - 142
  • [22] NEUROPEPTIDE-Y(18-36) MODULATES CHROMAFFIN CELL CATECHOLAMINE SECRETION BY BLOCKING THE NICOTINIC RECEPTOR-ION CHANNEL
    ZHENG, JL
    MORRISETT, RA
    ZHU, JH
    HEXUM, TD
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 274 (02): : 891 - 897
  • [23] Enhancement of secretion by threshold nicotinic stimulation in bovine chromaffin cells
    Tapia, Laura
    Eguiagaray, Josefina Garcia
    Egea, Javier
    Garcia, Antonio Garcia
    Gandia, Luis
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2006, 30 (1-2) : 81 - 82
  • [24] Enhancement of secretion by threshold nicotinic stimulation in bovine chromaffin cells
    Laura Tapia
    Josefina García Eguiagaray
    Javier Egea
    Antonio García García
    Luis Gandía
    Journal of Molecular Neuroscience, 2006, 30 : 81 - 82
  • [25] NICOTINIC RECEPTOR-MEDIATED INTRACELLULAR CALCIUM RELEASE IN CULTURED BOVINE ADRENAL CHROMAFFIN CELLS
    SASAKAWA, N
    ISHII, K
    KATO, R
    NEUROSCIENCE LETTERS, 1986, 63 (03) : 275 - 279
  • [26] A single neuronal nicotinic receptor α3α7β4*is present in the bovine chromaffin cell
    Maneu, V
    Rojo, J
    Mulet, J
    Valor, LM
    Sala, F
    Criado, M
    García, AG
    Gandía, L
    CHROMAFFIN CELL: TRNSMITTER BIOSYNTHESIS, STORAGE, RELEASE, ACTIONS, AND INFORMATICS, 2002, 971 : 165 - 167
  • [27] Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y-1 receptor
    Sautel, M
    Rudolf, K
    Wittneben, H
    Herzog, H
    Martinez, R
    Munoz, M
    Eberlein, W
    Engel, W
    Walker, P
    BeckSickinger, AG
    MOLECULAR PHARMACOLOGY, 1996, 50 (02) : 285 - 292
  • [28] Inhibition of Parietal Cell Acid Secretion Is Mediated by the Classical Epidermal Growth Factor Receptor
    Virendra Joshi
    Gregory S. Ray
    James R. Goldenring
    Digestive Diseases and Sciences, 1997, 42 : 1194 - 1198
  • [29] Inhibition of parietal cell acid secretion is mediated by the classical epidermal growth factor receptor
    Joshi, V
    Ray, GS
    Goldenring, JR
    DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (06) : 1194 - 1198
  • [30] Effects of the neuropeptide Y (NPY)-receptor antagonist BIBP3226 on vascular NPY-receptors with different ligand requirements
    Grundemar, L
    Ekelund, M
    PHARMACOLOGY & TOXICOLOGY, 1996, 79 (05): : 266 - 269